#1 Clinical Trials Search in Europe

Sodium Zirconium Cyclosilicate

Sodium Zirconium Cyclosilicate (SZC), also known as Lokelma, is a medication being studied in clinical trials for its potential to treat hyperkalemia, a condition characterized by high levels of potassium in the blood. These trials are exploring SZC’s effectiveness in various patient populations, including those with chronic kidney disease, heart failure, and end-stage renal disease. The studies aim to evaluate SZC’s ability to lower and maintain normal potassium levels, as well as its safety profile and impact on quality of life for patients with hyperkalemia.

Table of Contents

What is Sodium Zirconium Cyclosilicate?

Sodium Zirconium Cyclosilicate, also known as SZC, ZS, or by its brand name Lokelma, is a medication used to treat high levels of potassium in the blood, a condition called hyperkalemia[1]. This drug is part of a class of medications called potassium binders, which help remove excess potassium from the body[2].

How Does It Work?

SZC works by binding to potassium in the digestive tract. When you take this medication, it travels through your stomach and intestines, where it attracts and holds onto excess potassium. This bound potassium is then eliminated from your body through your stool, effectively lowering the amount of potassium in your blood[1].

What Conditions Does It Treat?

Sodium Zirconium Cyclosilicate is primarily used to treat hyperkalemia, which is a higher than normal level of potassium in the blood. This condition can occur in people with:

  • Chronic Kidney Disease (CKD): When kidneys don’t function properly, they may not be able to remove excess potassium from the body[3].
  • Heart Failure: Some medications used to treat heart failure can cause potassium levels to rise[4].
  • Diabetes: This condition can affect kidney function and lead to high potassium levels[5].

SZC is also being studied for its potential to allow patients with these conditions to continue taking important medications that can sometimes cause hyperkalemia, such as drugs that block the renin-angiotensin-aldosterone system (RAAS inhibitors)[6].

How Is It Taken?

Sodium Zirconium Cyclosilicate is typically taken orally as a powder that is mixed with water to form a suspension. The dosage can vary depending on the individual’s needs and response to treatment. Common dosing regimens include:

  • Starting with a higher dose (like 10 grams three times a day) for a short period (24 to 72 hours) to quickly lower potassium levels[1].
  • Then moving to a lower maintenance dose (like 5 to 15 grams once daily) for longer-term management[1].

It’s important to take this medication exactly as prescribed by your healthcare provider. They will monitor your potassium levels regularly and adjust the dose as needed[1].

How Effective Is It?

Clinical trials have shown that Sodium Zirconium Cyclosilicate is effective in lowering and maintaining normal potassium levels in many patients. For example:

  • In one study, about 80% of patients achieved normal potassium levels within 24 to 48 hours of starting treatment[5].
  • Another study found that SZC was effective in maintaining normal potassium levels for up to 12 months in patients with chronic hyperkalemia[1].

However, as with all medications, individual results may vary, and your healthcare provider will work with you to determine if this treatment is effective for your specific situation.

What Are the Potential Side Effects?

While Sodium Zirconium Cyclosilicate is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Edema: Swelling due to fluid retention[6].
  • Gastrointestinal issues: Such as constipation, diarrhea, nausea, or abdominal pain[6].
  • Low potassium levels: In some cases, potassium levels may drop too low, a condition called hypokalemia[7].

It’s important to report any side effects to your healthcare provider. They can help determine if the benefits of the medication outweigh the risks for your individual case.

Ongoing Research and Future Applications

Researchers are continuing to study Sodium Zirconium Cyclosilicate for various applications. Some areas of ongoing research include:

  • Use in heart failure patients: Studies are looking at whether SZC can help patients with heart failure take higher doses of beneficial medications that can sometimes cause hyperkalemia[4].
  • Combination with diet modifications: Researchers are investigating whether SZC can allow patients with chronic kidney disease to eat a more potassium-rich diet, which could have other health benefits[3].
  • Use in dialysis patients: Studies are examining whether SZC can help manage potassium levels in patients undergoing dialysis[8].

These ongoing studies may lead to new uses for Sodium Zirconium Cyclosilicate in the future, potentially benefiting more patients with various conditions related to potassium imbalance.

Aspect Details
Drug Name Sodium Zirconium Cyclosilicate (SZC), also known as Lokelma
Primary Indication Treatment of hyperkalemia (high potassium levels in the blood)
Patient Populations Chronic kidney disease, heart failure, end-stage renal disease, post-parathyroidectomy
Administration Oral suspension, various dosing regimens (e.g., 5g, 10g, 15g daily)
Key Objectives Efficacy in lowering and maintaining normal potassium levels, safety profile, optimal dosing, impact on quality of life
Potential Benefits Rapid potassium lowering, maintenance of normokalemia, allowing continuation of important medications (e.g., RAASi), improved quality of life
Study Designs Randomized, placebo-controlled, double-blind, open-label, various durations (24 hours to 12 months)
Outcome Measures Serum potassium levels, time to normokalemia, proportion of patients achieving/maintaining normal potassium levels, adverse events

FAQ

  • What is Sodium Zirconium Cyclosilicate (SZC) and how does it work? Sodium Zirconium Cyclosilicate (SZC) is a medication designed to treat hyperkalemia, or high potassium levels in the blood. It works by binding to potassium ions in the gastrointestinal tract, increasing fecal potassium excretion and lowering serum potassium levels.
  • What patient populations are being studied in clinical trials using SZC? Clinical trials are studying SZC in various patient populations, including those with chronic kidney disease (CKD), heart failure, end-stage renal disease (ESRD) on hemodialysis, and patients undergoing parathyroidectomy. Some trials also focus on patients taking medications that can increase potassium levels, such as renin-angiotensin-aldosterone system inhibitors (RAASi).
  • What are the main goals of these clinical trials? The main goals of these clinical trials are to evaluate the efficacy of SZC in lowering and maintaining normal potassium levels, assess its safety profile, determine appropriate dosing regimens, and investigate its impact on quality of life for patients with hyperkalemia. Some trials also aim to explore whether SZC can allow patients to continue or optimize other important medications that may increase potassium levels.
  • How is SZC administered in these clinical trials? In most trials, SZC is administered orally as a suspension. The dosing varies between studies, but common regimens include 5g, 10g, or 15g once daily. Some trials use an initial higher dose (e.g., 10g three times daily) for a short period to correct hyperkalemia, followed by a lower maintenance dose.
  • What are some potential benefits of SZC being investigated in these trials? Potential benefits of SZC being investigated include its ability to rapidly lower and maintain normal potassium levels, allow patients to continue or optimize important medications like RAASi, improve quality of life, reduce the need for dietary potassium restrictions, and potentially decrease the risk of hyperkalemia-related complications. Some trials are also exploring whether SZC can help optimize the use of other medications beneficial for heart and kidney health.

Ongoing Clinical Trials on Sodium Zirconium Cyclosilicate

  • Study on Managing Heart Failure and Kidney Disease in Elderly Patients with High Potassium Risk Using Sodium Zirconium Cyclosilicate

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of sodium zirconium cyclosilicate compared to standard care for managing high blood potassium levels in patients with chronic kidney disease

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effectiveness of Sodium Zirconium Cyclosilicate for Children with High Potassium Levels

    Recruiting

    1 1 1 1
    Investigated drugs:
    Germany Poland Romania Spain

  • Study on Sodium Zirconium Cyclosilicate for Improving Heart Failure Treatment in Patients with High-Risk Hyperkalemia

    Not recruiting

    1 1
    Investigated drugs:
    Sweden

  • Study on Sodium Zirconium Cyclosilicate for Patients with Chronic Kidney Disease Stages 3b and 4 to Allow More Fruits and Vegetables in Their Diet

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Hyperkalemia: A condition characterized by higher than normal levels of potassium in the blood, which can be dangerous and potentially life-threatening.
  • Sodium Zirconium Cyclosilicate (SZC): A medication designed to treat hyperkalemia by binding to potassium ions in the gastrointestinal tract, increasing fecal potassium excretion and lowering serum potassium levels.
  • Chronic Kidney Disease (CKD): A long-term condition where the kidneys do not function properly, potentially leading to complications such as hyperkalemia.
  • End-Stage Renal Disease (ESRD): The final stage of chronic kidney disease where the kidneys have lost almost all of their ability to function effectively, requiring dialysis or kidney transplantation.
  • Hemodialysis: A medical procedure that filters waste products from the blood when the kidneys are not working properly, often used in patients with end-stage renal disease.
  • Renin-Angiotensin-Aldosterone System Inhibitors (RAASi): A class of medications used to treat conditions like high blood pressure and heart failure, which can sometimes increase the risk of hyperkalemia.
  • Mineralocorticoid Receptor Antagonists (MRA): A type of medication used in heart failure treatment that can increase potassium levels in the body.
  • Parathyroidectomy: A surgical procedure to remove one or more of the parathyroid glands, which can sometimes lead to changes in potassium levels.
  • Serum Potassium (S-K): The level of potassium measured in the blood serum, used to diagnose and monitor hyperkalemia.
  • Normokalemia: A state where blood potassium levels are within the normal range, typically between 3.5 and 5.0 mmol/L.
  • Quality of Life (QoL): A measure of an individual's overall well-being and ability to function in daily life, often assessed in clinical trials to determine the impact of a treatment.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.

References

  1. https://clinicaltrials.gov/study/NCT02163499
  2. https://clinicaltrials.gov/study/NCT02107092
  3. https://clinicaltrials.gov/study/NCT06365684
  4. https://clinicaltrials.eu/trial/study-on-sodium-zirconium-cyclosilicate-for-improving-heart-failure-treatment-in-patients-with-high-risk-hyperkalemia/
  5. https://clinicaltrials.gov/study/NCT02088073
  6. https://clinicaltrials.gov/study/NCT03532009
  7. https://clinicaltrials.gov/study/NCT03528681
  8. https://clinicaltrials.gov/study/NCT04217590